Consequently, we propose the hypothesis that DROSD induces the down-regulation of splenic immune function, resulting in a decrease in the number of CD8+ T lymphocytes, ultimately leading to poorer OS and DFS outcomes in colorectal cancer patients. This evidence concerns the gene CD8A and colorectal cancer.